Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acura Pharmaceuticals, Inc. (ACUR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3480-0.1820 (-34.34%)
At close: 12:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5300
Open0.5100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3200 - 0.5100
52 Week Range0.2900 - 0.7500
Volume21,460
Avg. Volume4,655
Market Cap22.651M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

    Amendment Extends NDA Acceptance DatePALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required s

  • GlobeNewswire

    Acura Pharmaceuticals Provides Development Update on LTX-03

    PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patente

  • GlobeNewswire

    Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

    PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for th

Advertisement
Advertisement